Belite Bio (BLTE) Expected to Announce Quarterly Earnings on Monday

Belite Bio (NASDAQ:BLTE - Get Free Report) is projected to release its earnings data before the market opens on Monday, March 10th. Analysts expect Belite Bio to post earnings of ($0.30) per share for the quarter.

Belite Bio Price Performance

NASDAQ BLTE traded down $0.03 on Monday, hitting $57.17. 112,015 shares of the stock were exchanged, compared to its average volume of 39,345. The company's 50-day moving average price is $58.06 and its two-hundred day moving average price is $59.27. Belite Bio has a 52-week low of $31.00 and a 52-week high of $86.53. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -51.50 and a beta of -1.59.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BLTE. Benchmark upped their target price on Belite Bio from $57.00 to $79.00 and gave the company a "buy" rating in a report on Tuesday, January 21st. HC Wainwright increased their target price on shares of Belite Bio from $60.00 to $100.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, Maxim Group lifted their target price on shares of Belite Bio from $60.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, November 15th.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.